WO1999021991A1 - Bmzf12: gene a doigt de zinc clone a partir de la moelle osseuse - Google Patents

Bmzf12: gene a doigt de zinc clone a partir de la moelle osseuse Download PDF

Info

Publication number
WO1999021991A1
WO1999021991A1 PCT/CN1997/000119 CN9700119W WO9921991A1 WO 1999021991 A1 WO1999021991 A1 WO 1999021991A1 CN 9700119 W CN9700119 W CN 9700119W WO 9921991 A1 WO9921991 A1 WO 9921991A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
bmzf12
bmzf
seq
nucleotide sequence
Prior art date
Application number
PCT/CN1997/000119
Other languages
English (en)
Inventor
Ze-Guang Han
Ya-Xin Wang
Original Assignee
Shanghai Second Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Second Medical University filed Critical Shanghai Second Medical University
Priority to PCT/CN1997/000119 priority Critical patent/WO1999021991A1/fr
Publication of WO1999021991A1 publication Critical patent/WO1999021991A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • BMZF12 A ZINC FINGER GENE CLONED FROM BONE MARROW
  • This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, die polynucleotides and polypeptides of the present invention relate to die zinc finger gene family, hereinafter referred to as BMZF12. The invention also relates to inhibiting or activating die action of such polynucleotides and polypeptides.
  • a typical zinc finger motif is the C2H2 motif, which consists of repeated domains of two invariant cysteines and two histidines, with a loop of variable length, but contairiing an invariant leucine and either a tyrosine or phenylalanine located within each loop.
  • Zinc finger proteins can bind directiy to the DNA double helix.
  • the transcription factor J UIA is one example of a C2H2 zinc finger protein, and die first identified C2H2 protein.
  • the C2H2 zinc finger motif has also been identified in a number of odier transcription factors, presumed transcription factors, and steriod receptors.
  • the invention relates to BMZF12 polypeptides and recombinant materials and methods for tiieir production.
  • Anotiier aspect of die invention relates to metiiods for using such BMZF12 polypeptides and polynucleotides. Such uses include the treatment of leukemia, among otiiers.
  • die invention relates to metiiods to identify agonists and antagonists using die materials provided by the invention, and treating conditions associated witii BMZF12 imbalance with the identified compounds.
  • Yet another aspect of die invention relates to diagnostic assays for detecting diseases associated with inappropriate BMZF12 activity or levels.
  • BMZF12 refers, among others, generally to a polypeptide having the amino acid sequence set forth in SEQ ID NO:2 or an allelic variant thereof.
  • BMZF12 activity or BMZF12 polypeptide activity or “biological activity of the BMZF12 or BMZF12 polypeptide” refers to the metabolic or physiologic function of said BMZF12 including similar activities or improved activities or tiiese activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said BMZF12.
  • MZF12 gene refers to a polynucleotide having the nucleotide sequence set forth in SEQ ID NO: 1 or allelic variants tiiereof and/or tiieir complements.
  • Antibodies as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.
  • Isolated means altered “by the hand of man” from the natural state. If an "isolated” composition or substance occurs in nature, it has been changed or removed from its original environment, or both.
  • a polynucleotide or a polypeptide naturally present in a living animal is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated”, as the term is employed herein.
  • Polynucleotide generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
  • Polynucleotides include, without limitation single- and double-stranded DNA, DNA tiiat is a mixture of single- and double- stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.
  • polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA.
  • the term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs witii backbones modified for stability or for other reasons.
  • Modified bases include, for example, tritylated bases and unusual bases such as inosine.
  • polynucleotide embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells.
  • Polynucleotide also embraces relatively short polynucleotides, often referred to as oligonucleotides.
  • Polypeptide refers to any peptide or protein comprising two or more amino acids joined to each otiier by peptide bonds or modified peptide bonds, i.e., peptide isosteres.
  • Polypeptide refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids.
  • Polypeptides include amino acid sequences modified eitiier by natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in die art.
  • Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and die amino or carboxyl termini. It will be appreciated tiiat the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or witiiout branching.
  • Cyclic, branched and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic metiiods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma- carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation,
  • Variant is a polynucleotide or polypeptide tiiat differs from a reference polynucleotide or polypeptide respectively, but retains essential properties.
  • a typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below.
  • a typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical.
  • a variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination.
  • a substituted or inserted amino acid residue may or may not be one encoded by the genetic code.
  • a variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant tiiat is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.
  • Identity is a measure of die identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. “Identity” per se has an art-recognized meaning and can be calculated using published techniques.
  • identity is well known to skilled artisans (Carillo, H., and Lipton, D., SIAM J Applied Math (1988) 48:1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, tiiose disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., SIAM J Applied Math (1988) 48:1073. Methods to determine identity and similarity are codified in computer programs.
  • Preferred computer program metiiods to determine identity and similarity between two sequences include, but are not limited to, GCS program package (Devereux, J., et al. , Nucleic Acids Research (1984) 12(1):387), BLASTP, BLASTN, FASTA (Atschul, S.F. et al, JMolec Biol (1990) 215:403).
  • a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO: 1 is intended tiiat the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO: 1.
  • a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of die total nucleotides in the reference sequence may be inserted into the reference sequence.
  • These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups witiiin the reference sequence.
  • a polypeptide having an amino acid sequence having at least, for example, 95% "identity" to a reference amino acid sequence of SEQ ID NO:2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: 2.
  • up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence.
  • These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
  • the present invention relates to BMZF12 polypeptides (or BMZF12 proteins).
  • the BMZF12 polypeptides include the polypeptide of SEQ ID NO:2; as well as polypeptides comprising the amino acid sequence of SEQ ID NO: 2; and polypeptides comprising the amino acid sequence which have at least 80% identity to that of SEQ ID NO:2 over its entire length, and still more preferably at least 90% identity, and even still more preferably at least 95% identity to SEQ ID NO: 2.
  • tiiose with at least 97-99% are highly preferred.
  • BMZF12 polypeptides having die amino acid sequence which have at least 80% identity to the polypeptide having the amino acid sequence of SEQ ID NO:2 over its entire length, and still more preferably at least 90% identity, and still more preferably at least 95% identity to SEQ ID NO:2. Furthermore, tiiose witii at least 97-99% are highly preferred.
  • BMZF12 polypeptide exhibit at least one biological activity of BMZF12.
  • the BMZF12 polypeptides may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.
  • a fragment is a polypeptide having an amino acid sequence that entirely is the same as part, but not all, of die amino acid sequence of the aforementioned BMZF12 polypeptides.
  • fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region.
  • Representative examples of polypeptide fragments of the invention include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, and 101 to die end of BMZF12 polypeptide.
  • “about” includes the particularly recited ranges larger or smaller by several, 5, 4, 3, 2 or 1 amino acid at either extreme or at botii extremes.
  • Preferred fragments include, for example, truncation polypeptides having the amino acid sequence of BMZF12 polypeptides, except for deletion of a continuous series of residues that includes the amino terminus, or a continuous series of residues tiiat includes d e carboxyl terminus or deletion of two continuous series of residues, one including the amino terminus and one including the carboxyl terminus.
  • fragments characterized by structural or functional attributes such as fragments tiiat comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and iim-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-fo ⁇ ing regions, substrate binding region, and high antigenic index regions.
  • Other preferred fragments are biologically active fragments.
  • Biologically active fragments are those that mediate BMZF12 activity, including tiiose with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those that are antigenic or immunogenic in an animal, especially in a human.
  • variants are those that vary from the referents by conservative amino acid substitutions -- i.e., those that substitute a residue with another of like characteristics. Typical such substitutions are among Ala, Val, Leu and He; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gin; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination.
  • the BMZF12 polypeptides of the invention can be prepared in any suitable manner.
  • Such polypeptides include isolated naturally occurring polypeptides, recombinantiy produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.
  • BMZF12 polynucleotides include isolated polynucleotides which encode the BMZF 12 polypeptides and fragments, and polynucleotides closely related thereto. More specifically, BMZF12 polynucleotide of the invention include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO: 1 encoding a BMZF 12 polypeptide of SEQ ID NO: 2, and polynucleotide having d e particular sequence of SEQ ID NO: 1.
  • BMZF 12 polynucleotides further include a polynucleotide comprising a nucleotide sequence that has at least 80% identity over its entire length to a nucleotide sequence encoding the BMZF12 polypeptide of SEQ ED NO:2, and a polynucleotide comprising a nucleotide sequence that is at least 80% identical to of SEQ ID NO: 1 over its entire length.
  • polynucleotides at least 90% identical are particularly preferred, and those with at least 95% are especially preferred.
  • those witii at least 97% are highly preferred and those with at least 98-99% are most highly preferred, with at least 99% being the most preferred.
  • BMZF 12 polynucleotides are a nucleotide sequence which has sufficient identity to a nucleotide sequence contained in SEQ ID NO: 1 to hybridize under conditions useable for amplification or for use as a probe or marker.
  • the invention also provides polynucleotides which are complementary to such BMZF12 polynucleotides.
  • BMZF 12 of the invention is structurally related to other proteins of the zinc finger gene family, as shown by the results of sequencing die cDNA of Table 1 (SEQ ID NO: 1) encoding human BMZF12.
  • the cDNA sequence of SEQ ID NO: 1 contains an open reading frame (nucleotide number 3 to 827) encoding a polypeptide of 275 amino acids of SEQ ID NO:2.
  • the amino acid sequence of Table 2 (SEQ ED NO:2) has about 72% identity (using FASTA) in 258 amino acid residues with human zinc finger protein ZN85 (D.A. Poncelet et al. Proc. Nati. Acad. Sci. USA, 88:3608-3612,1991).
  • BMZF12 polypeptides and polynucleotides of the present invention are expected to have, inter alia, similar biological functions/properties to their homologous polypeptides and polynucleotides, and their utility is obvious to anyone skilled in the art.
  • a nucleotide sequence of a human BMZF12. SEQ ID NO: 1.
  • One polynucleotide of the present invention encoding BMZF 12 may be obtained using standard cloning and screening, from a cDNA library derived from mRNA in cells of human bone marrow using the expressed sequence tag (EST) analysis (Adams, M.D., et al. Science (1991) 252:1651-1656; Adams, M.D. et al, Nature, (1992) J55:632-634; Adams, M.D., et al, Nature (1995) 377 Supp:3-174).
  • Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.
  • the nucleotide sequence encoding BMZF 12 polypeptide of SEQ ID NO: 2 may be identical to the polypeptide encoding sequence contained in Table 1 (nucleotide number 3 to 827 of SEQ ID NO:l), or it may be a sequence, which as a result of the redundancy (degeneracy) of d e genetic code, also encodes the polypeptide of SEQ ID NO:2.
  • the polynucleotide may include the coding sequence for the mature polypeptide or a fragment thereof, by itself; the coding sequence for the mature polypeptide or fragment in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions.
  • a marker sequence which facilitates purification of the fused polypeptide can be encoded.
  • the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al., Proc NatlAcadSci USA (1989) 86:821-824, or is an HA tag.
  • the polynucleotide may also contain non-coding 5' and 3 ' sequences, such as transcribed, non- translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.
  • polynucleotides encoding BMZF 12 variants comprise the amino acid sequence BMZF12 polypeptide of Table 2 (SEQ ID NO:2) in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acid residues are substituted, deleted or added, in any combination.
  • the present invention further relates to polynucleotides that hybridize to the herein above- described sequences.
  • the present invention especially relates to polynucleotides which hybridize under stringent conditions to the herein above-described polynucleotides.
  • stringent conditions means hybridization will occur only rf there is at least 80%, and preferably at least 90%, and more preferably at least 95%, yet even more preferably 97-99% identity between the sequences.
  • Polynucleotides of the invention which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO: 1 or a fragment thereof, may be used as hybridization probes for cDNA and genomic DNA, to isolate full-length cDNAs and genomic clones encoding BMZF 12 polypeptide and to isolate cDNA and genomic clones of other genes (including genes encoding homologs and orthologs from species other than human) that have a high sequence similarity to the BMZF 12 gene.
  • hybridization techniques are known to those of skill in the art.
  • these nucleotide sequences are 80% identical, preferably 90% identical, more preferably 95% identical to that of the referent.
  • the probes generally will comprise at least 15 nucleotides.
  • such probes will have at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will range between 30 and 50 nucleotides.
  • BMZF12 polynucleotides of the present invention further include a nucleotide sequence comprising a nucleotide sequence that hybridize under stringent condition to a nucleotide sequence having SEQ ID NO: 1 or a fragment thereof.
  • polypeptides comprising amino acid sequence encoded by nucleotide sequence obtained by the above hybridization condition.
  • hybridization techniques are well known to those of skill in the art.
  • Stringent hybridization conditions are as defined above or, alternatively, conditions under overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 ltiM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0. lx SSC at about 65°C.
  • polynucleotides and polypeptides of the present invention may be employed as research reagents and materials for discovery of treatments and diagnostics to animal and human disease.
  • Vectors, Host Cells, Expression also relates to vectors which comprise a polynucleotide or polynucleotides of the present invention, and host cells which are genetically engineered with vectors of the invention and to the production of polypeptides of the invention by recombinant techniques.
  • Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.
  • host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention.
  • polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et aL, BASIC METHODS IN MOLECULAR BIOLOGY (1986) and Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. ( 1989) such as calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.
  • methods described in many standard laboratory manuals such as Davis et aL, BASIC METHODS IN MOLECULAR BIOLOGY (1986) and Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. ( 1989) such as calcium phosphate transfection, DEAE
  • bacterial cells such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells
  • fungal cells such as yeast cells and Aspergillus cells
  • insect cells such as Drosophila S2 and Spodoptera Sf9 cells
  • animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells
  • plant cells include bacterial cells, such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells
  • fungal cells such as yeast cells and Aspergillus cells
  • insect cells such as Drosophila S2 and Spodoptera Sf9 cells
  • animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells
  • Such systems include, among others, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids.
  • viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses
  • vectors derived from combinations thereof such as those derived from plasmid and bacteriophage genetic elements, such as cosmid
  • the expression systems may contain control regions that regulate as well as engender expression.
  • any system or vector suitable to maintain, propagate or express polynucleotides to produce a polypeptide in a host may be used.
  • the appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al, MOLECULAR CLONING, A LABORATORY MANUAL (supra).
  • appropriate secretion signals may be incorporated into the desired polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.
  • the polypeptide be produced at the surface of the cell.
  • the cells may be harvested prior to use in the screening assay. If BMZF12 polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide; if produced intracellularly, the cells must first be lysed before the polypeptide is recovered.
  • BMZF 12 polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.
  • This invention also relates to the use of BMZF12 polynucleotides for use as diagnostic reagents. Detection of a mutated form of BMZF12 gene associated with a dysfunction will provide a diagnostic tool that can add to or define a diagnosis of a disease or susceptibility to a disease which results from under-expression, over-expression or altered expression of BMZF12. Individuals carrying mutations in the BMZF 12 gene may be detected at the DNA level by a variety of techniques.
  • Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material.
  • the genomic DNA may be used directiy for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis.
  • RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled BMZF 12 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures.
  • DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g., Myers et al, Science (1985) 230:1242. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and SI protection or the chemical cleavage method. See Cotton etal, ProcNatlAcadSci USA (1985) 85: 4397-4401.
  • an array of oligonucleotides probes comprising BMZF12 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations.
  • the diagnostic assays offer a process for diagnosing or deterniining a susceptibility to leukemia through detection of mutation in the BMZF12 gene by the methods described.
  • leukemia can be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of BMZF 12 polypeptide or BMZF12 mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as an BMZF 12 polypeptide, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.
  • the present invention relates to a diagonostic kit for a disease or suspectability to a disease, particularly leukemia, which comprises:
  • BMZF 12 polynucleotide preferably the nucleotide sequence of SEQ ID NO: 1, or a fragment thereof ;
  • b a nucleotide sequence complementary to that of (a);
  • BMZF12 polypeptide preferably the polypeptide of SEQ ID NO: 2, or a fragment thereof;
  • the nucleotide sequences of the present invention are also valuable for chromosome identification.
  • the sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome.
  • the mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease.
  • the differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.
  • Antibodies The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them can also be used as immunogens to produce antibodies immunospecific for the BMZF 12 polypeptides.
  • immunospecific means that the antibodies have substantiall greater aflfinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.
  • Antibodies generated against the BMZF 12 polypeptides can be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a nonhuman, using routine protocols.
  • any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C, Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al, Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole et al. , MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985).
  • Antibodies against BMZF 12 polypeptides may also be employed to treat leukemia, among others.
  • Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with BMZF 12 polypeptide, or a fragment thereof, adequate to produce antibody and/or T cell immune response to protect said animal from leukemia, among others.
  • Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering BMZF 12 polypeptide via a vector directing expression of BMZF12 polynucleotide in vivo in order to induce such an immunological response to produce antibody to protect said animal from diseases.
  • composition which, when introduced into a mammalian host, induces an immunological response in that mammal to a BMZF12 polypeptide wherein the composition comprises a BMZF12 polypeptide or BMZF 12 gene.
  • the vaccine formulation may further comprise a suitable carrier. Since BMZF 12 polypeptide may be broken down in the stomach, it is preferably administered parenterally (including subcutaneous, intramuscular, intravenous, intradermal etc. injection).
  • Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render die formulation instonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.
  • the vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.
  • the BMZF 12 polypeptide of the present invention may be employed in a screening process for compounds which activate (agonists) or inhibit activation of (antagonists, or otherwise called inhibitors) the BMZF12 polypeptide of the present invention.
  • polypeptides of die invention may also be used to assess identify agonist or antagonists from, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures.
  • These agonists or antagonists may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide of the present invention; or may be structural or functional mimetics of the polypeptide of the present invention. See Coligan etal, Current Protocols in lmmunology l(2):Chapter 5 (1991).
  • BMZF12 polypeptides are responsible for many biological functions, including many pathologies. Accordingly, it is desirous to find compounds and drugs which stimulate BMZF 12 polypeptide on the one hand and which can inhibit the function of BMZF12 polypeptide on the other hand.
  • agonists are employed for therapeutic and prophylactic purposes for such conditions as leukemia.
  • Antagonists may be employed for a variety of therapeutic and prophylactic purposes for such conditions as leukemia.
  • such screening procedures may involve using appropriate cells which express the BMZF12 polypeptide or respond to BMZF12 polypeptide of the present invention.
  • Such cells include cells from mammals, yeast, Drosophila or E. coli.
  • Cells which express the BMZF 12 polypeptide (or cell membrane containing the expressed polypeptide) or respond to BMZF 12 polypeptide are then contacted with a test compound to observe binding, or stimulation or inhibition of a functional response.
  • the ability of the cells which were contacted with the candidate compounds is compared with the same cells which were not contacted for BMZF 12 activity.
  • the assays may simply test binding of a candidate compound wherein adherence to the cells bearing the BMZF12 polypeptide is detected by means of a label directly or indirectly associated with the candidate compound or in an assay involving competition with a labeled competitor. Further, these assays may test whether the candidate compound results in a signal generated by activation of the BMZF 12 polypeptide, using detection systems appropriate to the cells bearing the BMZF12 polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed.
  • the assays may simply comprise the steps of mixing a candidate compound witii a solution containing a BMZF 12 polypeptide to form a mixture, measuring BMZF 12 activity in the mixture, and comparing the BMZF12 activity of the mixture to a standard.
  • the BMZF 12 cDNA, protein and antibodies to the protein may also be used to configure assays for detecting the effect of added compounds on the production of BMZF 12 mRNA and protein in cells.
  • an ELISA may be constructed for measuring secreted or cell associated levels of BMZF 12 protein using monoclonal and polyclonal antibodies by standard methods known in the art, and this can be used to discover agents which may inhibit or enhance the production of BMZF12 (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.
  • BMZF12 also called antagonist or agonist, respectively
  • the BMZF 12 protein may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the BMZF 12 is labeled with a radioactive isotope (eg 1251), chemically modified (eg biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy.
  • a radioactive isotope eg 1251
  • chemically modified eg biotinylated
  • these binding assays can be used to identify agonists and antagonists of BMZF12 which compete with the binding of BMZF12 to its receptors, if any. Standard methods for conducting screening assays are well understood in the art.
  • BMZF12 polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the BMZF12 polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or small molecules which bind to the polypetide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.
  • the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for BMZF12 polypeptides; or compounds which decrease or enhance the production of BMZF12 polypeptides, which comprises:
  • a cell membrane expressing a BMZF12 polypeptide preferably that of SEQ ID NO: 2; or
  • This invention provides methods of treating abnormal conditions such as, leukemia, related to both an excess of and insufficient amounts of BMZF 12 polypeptide activity.
  • BMZF 12 polypeptide is in excess.
  • One approach comprises administering to a subject an inhibitor compound (antagonist) as hereinabove described along with a pharmaceutically acceptable carrier in an amount effective to inhibit the function of the BMZF 12 polypeptide, such as, for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition.
  • soluble forms of BMZF12 polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous BMZF12 polypeptide may be administered. Typical embodiments of such competitors comprise fragments of the BMZF12 polypeptide.
  • expression of the gene encoding endogenous BMZF12 polypeptide can be inhibited using expression blocking techniques.
  • Known such techniques involve the use of antisense sequences, either internally generated or separately administered. See, for example, O'Connor, JNeurochem (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression. CRC Press, Boca Raton, FL (1988).
  • oligonucleotides which form triple helices with the gene can be supplied. See, for example, Lee et al, Nucleic Acids Res (1979) 3:173; Cooney et al, Science (1988) 241:456; Dervan et al, Science (1991) 251:1360. These oligomers can be administered per se or the relevant oligomers can be expressed in vivo.
  • BMZF 12 For treating abnormal conditions related to an under-expression of BMZF 12 and its activity, several approaches are also available.
  • One approach comprises administering to a subject a therapeutically effective amount of a compound which activates BMZF 12 polypeptide, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition.
  • gene therapy may be employed to effect the endogenous production of BMZF12 by the relevant cells in the subject.
  • a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above.
  • the retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest.
  • These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo.
  • Another approach is to administer a therapeutic amount of BMZF12 polypeptides in combination with a suitable pharmaceutical carrier.
  • Peptides such as the soluble form of BMZF 12 polypeptides, and agonists and antagonist peptides or small molecules, may be formulated in combination with a suitable pharmaceutical carrier.
  • suitable pharmaceutical carrier include but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. Formulation should suit the mode of administration, and is well within the skill of the art.
  • the invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.
  • Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.
  • systemic administration of the pharmaceutical compositions include injection, typically by intravenous injection.
  • Other injection routes such as subcutaneous, intramuscular, or intraperitoneal, can be used.
  • Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents.
  • penetrants such as bile salts or fusidic acids or other detergents.
  • oral adrninistration may also be possible.
  • Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels and the like.
  • the dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 ⁇ g/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of adrninistration. For example, oral adrninistration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.
  • Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above.
  • cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide ex vivo, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.
  • a polynucleotide such as a DNA or RNA

Abstract

L'invention concerne des polypeptides et des polynucléotides BMZF12 et des procédés de production de ces polypeptides par des techniques recombinantes. Font aussi l'objet de cette invention des procédés d'utilisation des polypeptides et des polynucléotides BMZF12 dans la conception de protocoles pour le traitement de la leucémie, entre autres, et des doses diagnostiques pour ces pathologies.
PCT/CN1997/000119 1997-10-29 1997-10-29 Bmzf12: gene a doigt de zinc clone a partir de la moelle osseuse WO1999021991A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN1997/000119 WO1999021991A1 (fr) 1997-10-29 1997-10-29 Bmzf12: gene a doigt de zinc clone a partir de la moelle osseuse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN1997/000119 WO1999021991A1 (fr) 1997-10-29 1997-10-29 Bmzf12: gene a doigt de zinc clone a partir de la moelle osseuse

Publications (1)

Publication Number Publication Date
WO1999021991A1 true WO1999021991A1 (fr) 1999-05-06

Family

ID=4575000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN1997/000119 WO1999021991A1 (fr) 1997-10-29 1997-10-29 Bmzf12: gene a doigt de zinc clone a partir de la moelle osseuse

Country Status (1)

Country Link
WO (1) WO1999021991A1 (fr)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027151A1 (fr) * 1999-10-10 2001-04-19 Shanghai Bio Door Gene Technology Ltd. Nouveau membre de la famille de type kruppel de proteine humaine a doigt de zinc zfp-52 et polynucleotide codant pour le nouveau membre
WO2001038378A1 (fr) * 1999-11-26 2001-05-31 Bioroad Gene Development Ltd. Shanghai Nouvelle proteine 69 a doigts de zinc polypeptidique et polynucleotide codant cette derniere
WO2001038375A1 (fr) * 1999-11-26 2001-05-31 Bioroad Gene Development Ltd. Shanghai Nouveau polypeptide, proteine a doigt de zinc 58 et polynucleotide codant pour ce polypeptide
WO2001038376A1 (fr) * 1999-11-26 2001-05-31 Bioroad Gene Development Ltd. Shanghai Nouveau polypeptide, proteine humaine a doigt de zinc 46, et polynucleotide codant pour ce polypeptide
WO2001040295A1 (fr) * 1999-11-30 2001-06-07 Bioroad Gene Development Ltd. Shanghai Nouveau polypeptide, proteine humaine 48 a doigt de zinc, et polynucleotide codant pour ce polypeptide
WO2001053497A1 (fr) * 2000-01-21 2001-07-26 Biodoor Gene Technology Ltd. Shanghai Nouveau polypeptide, proteine humaine 57 a doigt de zinc contenant un domaine structurel bola, et polynucleotide codant pour ce polypeptide
WO2001053341A1 (fr) * 2000-01-21 2001-07-26 Biodoor Gene Technology Ltd. Shanghai Nouveau polypeptide, proteine humaine 13 a doigt de zinc, et polynucleotide codant pour ce polypeptide
WO2001055188A1 (fr) * 2000-01-26 2001-08-02 Biodoor Gene Technology Ltd. Shanghai Nouveau polypeptide, proteine humaine a doigt de zinc 46, et polynucleotide codant pour ce polypeptide
WO2001055184A1 (fr) * 2000-01-26 2001-08-02 Biodoor Gene Technology Ltd. Shanghai Nouveau polypeptide, proteine humaine a doigt de zinc 19, et polynucleotide codant pour ce polypeptide
WO2001055187A1 (fr) * 2000-01-26 2001-08-02 Biodoor Gene Technology Ltd. Shanghai Nouveau polypeptide, proteine humaine 49 a doigt de zinc, et polynucleotide codant pour ce polypeptide
WO2001055426A1 (fr) * 2000-01-26 2001-08-02 Biodoor Gene Technology Ltd. Shanghai Nouveau polypeptide, proteine humaine 43 a doigt de zinc contenant un fragment de sequence tfiis specifique, et polynucleotide codant pour ce polypeptide
WO2001055186A1 (fr) * 2000-01-26 2001-08-02 Biodoor Gene Technology Ltd. Shanghai Nouveau polypeptide, proteine humaine a doigt de zinc 14, et polynucleotide codant pour ce polypeptide
WO2001066580A1 (fr) * 2000-03-07 2001-09-13 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine humaine 13 a doigt de zinc, et polynucleotide codant pour ce polypeptide
WO2001066582A1 (fr) * 2000-03-10 2001-09-13 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 27, et polynucleotide codant pour ce polypeptide
WO2001066583A1 (fr) * 2000-03-10 2001-09-13 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine 14 a doigt de zinc, et polynucleotide codant pour ce polypeptide
WO2001068690A1 (fr) * 2000-03-15 2001-09-20 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 15, et polynucleotide codant pour ce polypeptide
WO2001070802A1 (fr) * 2000-03-10 2001-09-27 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine a doigt de zinc 11, et polynucleotide codant pour ce polypeptide
WO2001072803A1 (fr) * 2000-03-28 2001-10-04 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 15, et polynucleotide codant pour ce polypeptide
WO2001072799A1 (fr) * 2000-03-27 2001-10-04 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 9, et polynucleotide codant pour ce polypeptide
WO2001094395A1 (fr) * 2000-05-16 2001-12-13 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 38, et polynucleotide codant ce polypeptide
WO2001094536A2 (fr) * 2000-05-24 2001-12-13 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 10.89, et polynucleotide codant ce polypeptide
WO2001096384A1 (fr) * 2000-05-16 2001-12-20 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 15, et polynucleotide codant ce polypeptide
WO2002004500A1 (fr) * 2000-06-19 2002-01-17 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine humaine a doigt de zinc fpm315-17, et polynucleotide codant ce polypeptide
WO2002004502A1 (fr) * 2000-06-19 2002-01-17 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine murine a doigt de zinc 16 (zfp-1), et polynucleotide codant ce polypeptide
WO2002010211A1 (fr) * 2000-06-30 2002-02-07 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 12.98, et polynucleotide codant ce polypeptide
WO2002020600A1 (fr) * 2000-06-28 2002-03-14 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 10.45, et polynucleotide codant ce polypeptide
WO2002020595A1 (fr) * 2000-06-12 2002-03-14 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine a doigt de zinc humaine 18.04, et polynucleotide codant ce polypeptide
WO2002026807A1 (fr) * 2000-07-07 2002-04-04 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine humaine a doigt de zinc de type kruppel 70.84, et polynucleotide codant ce polypeptide
WO2002040525A1 (fr) * 2000-06-30 2002-05-23 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 18.92, et polynucleotide codant ce polypeptide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019431A1 (fr) * 1994-01-18 1995-07-20 The Scripps Research Institute Derives de proteine a doigts zinciques et procedes associes
WO1996006166A1 (fr) * 1994-08-20 1996-02-29 Medical Research Council Ameliorations concernant des proteines de liaison permettant de reconnaitre l'adn
WO1996011267A1 (fr) * 1994-10-07 1996-04-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Adn et proteine a doigts de zinc et leur utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019431A1 (fr) * 1994-01-18 1995-07-20 The Scripps Research Institute Derives de proteine a doigts zinciques et procedes associes
WO1996006166A1 (fr) * 1994-08-20 1996-02-29 Medical Research Council Ameliorations concernant des proteines de liaison permettant de reconnaitre l'adn
WO1996011267A1 (fr) * 1994-10-07 1996-04-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Adn et proteine a doigts de zinc et leur utilisation

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027151A1 (fr) * 1999-10-10 2001-04-19 Shanghai Bio Door Gene Technology Ltd. Nouveau membre de la famille de type kruppel de proteine humaine a doigt de zinc zfp-52 et polynucleotide codant pour le nouveau membre
WO2001038378A1 (fr) * 1999-11-26 2001-05-31 Bioroad Gene Development Ltd. Shanghai Nouvelle proteine 69 a doigts de zinc polypeptidique et polynucleotide codant cette derniere
WO2001038375A1 (fr) * 1999-11-26 2001-05-31 Bioroad Gene Development Ltd. Shanghai Nouveau polypeptide, proteine a doigt de zinc 58 et polynucleotide codant pour ce polypeptide
WO2001038376A1 (fr) * 1999-11-26 2001-05-31 Bioroad Gene Development Ltd. Shanghai Nouveau polypeptide, proteine humaine a doigt de zinc 46, et polynucleotide codant pour ce polypeptide
WO2001040295A1 (fr) * 1999-11-30 2001-06-07 Bioroad Gene Development Ltd. Shanghai Nouveau polypeptide, proteine humaine 48 a doigt de zinc, et polynucleotide codant pour ce polypeptide
WO2001053497A1 (fr) * 2000-01-21 2001-07-26 Biodoor Gene Technology Ltd. Shanghai Nouveau polypeptide, proteine humaine 57 a doigt de zinc contenant un domaine structurel bola, et polynucleotide codant pour ce polypeptide
WO2001053341A1 (fr) * 2000-01-21 2001-07-26 Biodoor Gene Technology Ltd. Shanghai Nouveau polypeptide, proteine humaine 13 a doigt de zinc, et polynucleotide codant pour ce polypeptide
WO2001055188A1 (fr) * 2000-01-26 2001-08-02 Biodoor Gene Technology Ltd. Shanghai Nouveau polypeptide, proteine humaine a doigt de zinc 46, et polynucleotide codant pour ce polypeptide
WO2001055184A1 (fr) * 2000-01-26 2001-08-02 Biodoor Gene Technology Ltd. Shanghai Nouveau polypeptide, proteine humaine a doigt de zinc 19, et polynucleotide codant pour ce polypeptide
WO2001055187A1 (fr) * 2000-01-26 2001-08-02 Biodoor Gene Technology Ltd. Shanghai Nouveau polypeptide, proteine humaine 49 a doigt de zinc, et polynucleotide codant pour ce polypeptide
WO2001055426A1 (fr) * 2000-01-26 2001-08-02 Biodoor Gene Technology Ltd. Shanghai Nouveau polypeptide, proteine humaine 43 a doigt de zinc contenant un fragment de sequence tfiis specifique, et polynucleotide codant pour ce polypeptide
WO2001055186A1 (fr) * 2000-01-26 2001-08-02 Biodoor Gene Technology Ltd. Shanghai Nouveau polypeptide, proteine humaine a doigt de zinc 14, et polynucleotide codant pour ce polypeptide
WO2001066580A1 (fr) * 2000-03-07 2001-09-13 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine humaine 13 a doigt de zinc, et polynucleotide codant pour ce polypeptide
WO2001066583A1 (fr) * 2000-03-10 2001-09-13 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine 14 a doigt de zinc, et polynucleotide codant pour ce polypeptide
WO2001066582A1 (fr) * 2000-03-10 2001-09-13 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 27, et polynucleotide codant pour ce polypeptide
WO2001070802A1 (fr) * 2000-03-10 2001-09-27 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine a doigt de zinc 11, et polynucleotide codant pour ce polypeptide
WO2001068690A1 (fr) * 2000-03-15 2001-09-20 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 15, et polynucleotide codant pour ce polypeptide
WO2001072799A1 (fr) * 2000-03-27 2001-10-04 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 9, et polynucleotide codant pour ce polypeptide
WO2001072803A1 (fr) * 2000-03-28 2001-10-04 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 15, et polynucleotide codant pour ce polypeptide
WO2001094395A1 (fr) * 2000-05-16 2001-12-13 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 38, et polynucleotide codant ce polypeptide
WO2001096384A1 (fr) * 2000-05-16 2001-12-20 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 15, et polynucleotide codant ce polypeptide
WO2001094536A2 (fr) * 2000-05-24 2001-12-13 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 10.89, et polynucleotide codant ce polypeptide
WO2001094536A3 (fr) * 2000-05-24 2002-04-04 Shanghai Biowindow Gene Dev Nouveau polypeptide, proteine humaine a doigt de zinc 10.89, et polynucleotide codant ce polypeptide
WO2002020595A1 (fr) * 2000-06-12 2002-03-14 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine a doigt de zinc humaine 18.04, et polynucleotide codant ce polypeptide
WO2002004502A1 (fr) * 2000-06-19 2002-01-17 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine murine a doigt de zinc 16 (zfp-1), et polynucleotide codant ce polypeptide
WO2002004500A1 (fr) * 2000-06-19 2002-01-17 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine humaine a doigt de zinc fpm315-17, et polynucleotide codant ce polypeptide
WO2002020600A1 (fr) * 2000-06-28 2002-03-14 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 10.45, et polynucleotide codant ce polypeptide
WO2002010211A1 (fr) * 2000-06-30 2002-02-07 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 12.98, et polynucleotide codant ce polypeptide
WO2002040525A1 (fr) * 2000-06-30 2002-05-23 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine a doigt de zinc 18.92, et polynucleotide codant ce polypeptide
WO2002026807A1 (fr) * 2000-07-07 2002-04-04 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine humaine a doigt de zinc de type kruppel 70.84, et polynucleotide codant ce polypeptide

Similar Documents

Publication Publication Date Title
US6319688B1 (en) Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)
WO1999021991A1 (fr) Bmzf12: gene a doigt de zinc clone a partir de la moelle osseuse
EP0848062A2 (fr) Protéase aspartique ASP1
EP0897002A2 (fr) U62317, une protéine avec un domaine se liant à JNK
EP0854191A2 (fr) Protéine humaine du type cardiac/cerveau-tolloid
US5952483A (en) Human IκB-β
EP0846764A2 (fr) Famille de facteurs alpha neurotrophiques des cellules gliales
US5837508A (en) Membrane-type matrix metalloproteinase-5 gene
EP1002865A1 (fr) Protéine spécifique au tissu adipeux
CA2247799A1 (fr) Polynucleotides et polypeptides appartenant a la famille des proteines non liantes
CA2230996A1 (fr) Composes nouveaux
US6342584B1 (en) Human pelota homolog
US5932446A (en) Hmvab41
EP0897982A2 (fr) Co-transporteurs de bicarbonate de sodium
WO1999021988A1 (fr) Gene sec22b humain de cbfbba01 de la proteine d'echange vesiculaire
EP0894856A1 (fr) Variante d'épissure de sMAD3 humaine
WO1999022006A1 (fr) Cblafc02: sous-unite de h(+)-atpase vacuolaire
WO1999046290A1 (fr) Gene humain de type recepteur d'angiotensine ii/vasopreessine (aii/avp) (cbdakd01)
WO1999021885A1 (fr) Gene transporteur 7 abc humain (habc7)
EP0879886A2 (fr) HLDAT86, Protéine de la transduction de signaux et homoloque humaine de Wnt-4
US20020019520A1 (en) CBFBGA09: a human SL15 homolog
WO1999021982A1 (fr) Gene m6b1 humain
WO1999036522A1 (fr) Gene a faible similitude avec la tropomyosine (cbcadb07)
EP0892050A2 (fr) HFIZG53 humaine
EP0889126A2 (fr) Polypeptide YNL075W/HTXFT19

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09029765

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase